resisttb
- May 10
- 1 min read

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend patent on lifesaving

Doctors Without Borders/Médecins Sans Frontières (MSF) applauds today’s news that the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the tuberculosis (TB) drug bedaquiline beyond when its primary patent expires in July. The rejection is a significant step toward increasing access to the lifesaving TB drug. Read more here.

Recent Posts

See All

Why is a curable disease allowed to kill millions?

John Green, the author of several books and a longtime supporter of Partners in Health, discusses his time visiting Sierra Leone’s Lakka Government Hospital, a tuberculosis treatment center. He talks

International consensus highlights the importance of molecular testing for MDR-TB

A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibio

Sweet advance for treatment of children with multi-drug resistant TB

Children with multi-drug resistant tuberculosis (MDR-TB) undergo months of life-saving treatment including many doses of foul-tasting medications, which caregivers often struggle to prepare and admini